Article Text

Download PDFPDF

2022-RA-877-ESGO Epidemiological study on oncological outcome of patients with incidental findings of borderline ovarian tumors or ovarian cancer treated with a two-step surgical procedure
Free
  1. Franziska Siegenthaler1,
  2. Céline Smaadahl-Wey1,
  3. Lara Zumwald2,
  4. Sara Imboden1 and
  5. Michael David Mueller1
  1. 1Department of Obstetrics and Gynecology, Bern University Hospital and University of Bern, Bern, Switzerland
  2. 2University of Bern, Bern, Switzerland

Abstract

Introduction/Background Centralization of ovarian cancer (OVCA) treatment is known to be associated with prolonged survival. However, preoperative diagnosis might be challenging and sometimes the diagnosis is made unexpectedly after histological work-up. Aim of this study is to evaluate the oncological outcome of patients with incidental findings of OVCA or borderline ovarian tumors (BOT).

Abstract Table 1

Baseline clinicopathological characterists among the different study groups

Methodology This epidemiological study includes patients with suspicious adnexal mass undergoing surgical treatment at the Bern University Hospital, Switzerland between 2010 and 2020. Patients were allocated in two groups as follows (figure 1): group 1 consists of patients referred to our tertiary institution preoperatively due to suspected malignancy. Group 2 comprises patients with incidental findings of OVCA or BOT operated at a non-tertiary center that were referred to our institution postoperatively for completion of surgical staging and adjuvant treatment.

Abstract 2022-RA-877-ESGO Figure 1
Abstract 2022-RA-877-ESGO Table 1

Baseline clinicopathological characterists among the different study groups

Results Out of 390 patients, 224 were diagnosed with BOT or OVCA. Clinicopathological data are provided in Table 1, mean follow-up was 63 months. Compared to patients in group 1, patients in group 2 underwent a higher number of surgical interventions (2.1 vs. 1.3, P < .001), showed a longer time from diagnosis until start of chemotherapy (45 vs. 33 days, P= .006), and from diagnosis until completion of staging surgery (73 vs. 32 days, P < .001). Incidental diagnosis was not associated with increased risk of recurrence in patients with BOT (HR 4.6, 95% CI 0.4–52.3, P= .216), early stage (HR 0.6, 95% CI 0.2–1.7, P= .348) or advanced stage (HR 0.9, 95% CI 0.5–1.5, P= .631) OVCA.

Conclusion Although patients with incidental findings of OVCA or BOT have a longer time until completion of surgical staging and start of chemotherapy our results showed no compromise in oncological outcome. Our findings further highlight the importance of an untimely referral of these patients to a tertiary centre.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.